Insider Transactions in Q1 2025 at Novo Cure LTD (NVCR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Ashley Cordova Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
151,181
+29.86%
|
$2,721,258
$18.19 P/Share
|
|
Mar 04
2025
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+39.52%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+21.68%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+19.9%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+25.14%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+24.04%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Nicolas Leupin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+34.34%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Christoph Brackmann Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+31.21%
|
$989,550
$18.19 P/Share
|
|
Mar 03
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
250
-0.85%
|
$4,500
$18.54 P/Share
|
|
Mar 03
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,053
-1.0%
|
$36,954
$18.54 P/Share
|
|
Mar 03
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,527
-1.73%
|
$45,486
$18.54 P/Share
|
|
Mar 03
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
268
-0.16%
|
$4,824
$18.92 P/Share
|
|
Feb 28
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
368
-1.24%
|
$6,624
$18.28 P/Share
|
|
Feb 28
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,341
-1.12%
|
$42,138
$18.28 P/Share
|
|
Feb 28
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,770
-1.86%
|
$49,860
$18.28 P/Share
|
|
Feb 28
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,637
-1.36%
|
$83,466
$18.55 P/Share
|
|
Feb 27
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,646
-2.64%
|
$32,920
$20.24 P/Share
|
|
Feb 27
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,153
-2.56%
|
$223,060
$20.24 P/Share
|
|
Feb 27
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
12,266
-3.85%
|
$245,320
$20.24 P/Share
|
|
Feb 27
2025
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,387
-0.63%
|
$27,740
$20.24 P/Share
|
|
Feb 27
2025
|
Nicolas Leupin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
991
-0.97%
|
$19,820
$20.24 P/Share
|
|
Jan 11
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,160
-6.43%
|
$56,160
$26.81 P/Share
|
|
Jan 01
2025
|
Asaf Danziger |
BUY
Grant, award, or other acquisition
|
Direct |
400,000
+49.04%
|
-
|